378 related articles for article (PubMed ID: 20466735)
1. Methylation profile of TP53 regulatory pathway and mtDNA alterations in breast cancer patients lacking TP53 mutations.
Barekati Z; Radpour R; Kohler C; Zhang B; Toniolo P; Lenner P; Lv Q; Zheng H; Zhong XY
Hum Mol Genet; 2010 Aug; 19(15):2936-46. PubMed ID: 20466735
[TBL] [Abstract][Full Text] [Related]
2. Number of somatic mutations in the mitochondrial D-loop region indicates poor prognosis in breast cancer, independent of TP53 mutation.
Kuo SJ; Chen M; Ma GC; Chen ST; Chang SP; Lin WY; Chen YC; Lee TH; Lin TT; Liu CS
Cancer Genet Cytogenet; 2010 Sep; 201(2):94-101. PubMed ID: 20682393
[TBL] [Abstract][Full Text] [Related]
3. Wip1 over-expression correlated with TP53/p14(ARF) pathway disruption in human astrocytomas.
Wang P; Rao J; Yang H; Zhao H; Yang L
J Surg Oncol; 2011 Nov; 104(6):679-84. PubMed ID: 21695702
[TBL] [Abstract][Full Text] [Related]
4. Deregulation of the TP53/p14ARF tumor suppressor pathway in low-grade diffuse astrocytomas and its influence on clinical course.
Watanabe T; Katayama Y; Yoshino A; Komine C; Yokoyama T
Clin Cancer Res; 2003 Oct; 9(13):4884-90. PubMed ID: 14581362
[TBL] [Abstract][Full Text] [Related]
5. Association of interindividual differences in p14ARF promoter methylation with single nucleotide polymorphism in primary colorectal cancer.
Kang MY; Lee BB; Ji YI; Jung EH; Chun HK; Song SY; Park SE; Park J; Kim DH
Cancer; 2008 Apr; 112(8):1699-707. PubMed ID: 18327804
[TBL] [Abstract][Full Text] [Related]
6. Association of the germline TP53 R72P and MDM2 SNP309 variants with breast cancer survival in specific breast tumor subgroups.
van den Broek AJ; Broeks A; Horlings HM; Canisius SV; Braaf LM; Langerød A; Van't Veer LJ; Schmidt MK
Breast Cancer Res Treat; 2011 Nov; 130(2):599-608. PubMed ID: 21667122
[TBL] [Abstract][Full Text] [Related]
7. Association of sporadic breast cancer with PTEN/MMAC1/TEP1 promoter hypermethylation.
Sadeq V; Isar N; Manoochehr T
Med Oncol; 2011 Jun; 28(2):420-3. PubMed ID: 20237868
[TBL] [Abstract][Full Text] [Related]
8. The novel TP53 3'-end methylation pattern associated with its expression would be a potential biomarker for breast cancer detection.
Zeng F; Heng J; Guo X; Wang Y; Wu W; Tang L; Chen M; Wang S; Deng H; Wang J
Breast Cancer Res Treat; 2020 Feb; 180(1):237-245. PubMed ID: 31983017
[TBL] [Abstract][Full Text] [Related]
9. CHEK2 mutations affecting kinase activity together with mutations in TP53 indicate a functional pathway associated with resistance to epirubicin in primary breast cancer.
Chrisanthar R; Knappskog S; Løkkevik E; Anker G; Østenstad B; Lundgren S; Berge EO; Risberg T; Mjaaland I; Maehle L; Engebretsen LF; Lillehaug JR; Lønning PE
PLoS One; 2008 Aug; 3(8):e3062. PubMed ID: 18725978
[TBL] [Abstract][Full Text] [Related]
10. Genetic and methylation status of CDKN2A (p14
Chantre-Justino M; Gonçalves da Veiga Pires I; Cardoso Figueiredo M; Dos Santos Moreira A; Alves G; Faria Ornellas MH
Hum Pathol; 2022 Jan; 119():94-104. PubMed ID: 34826422
[TBL] [Abstract][Full Text] [Related]
11. Epigenetic and genetic burden measures are associated with tumor characteristics in invasive breast carcinoma.
O'Sullivan DE; Johnson KC; Skinner L; Koestler DC; Christensen BC
Epigenetics; 2016 May; 11(5):344-53. PubMed ID: 27070496
[TBL] [Abstract][Full Text] [Related]
12. Promoter hypermethylation of p16INK4A, p14ARF, CyclinD2 and Slit2 in serum and tumor DNA from breast cancer patients.
Sharma G; Mirza S; Prasad CP; Srivastava A; Gupta SD; Ralhan R
Life Sci; 2007 Apr; 80(20):1873-81. PubMed ID: 17383681
[TBL] [Abstract][Full Text] [Related]
13. Gene promoter and exon DNA methylation changes in colon cancer development - mRNA expression and tumor mutation alterations.
Molnár B; Galamb O; Péterfia B; Wichmann B; Csabai I; Bodor A; Kalmár A; Szigeti KA; Barták BK; Nagy ZB; Valcz G; Patai ÁV; Igaz P; Tulassay Z
BMC Cancer; 2018 Jun; 18(1):695. PubMed ID: 29945573
[TBL] [Abstract][Full Text] [Related]
14. Aberrant p16 promoter methylation in smokers and former smokers with nonsmall cell lung cancer.
Jarmalaite S; Kannio A; Anttila S; Lazutka JR; Husgafvel-Pursiainen K
Int J Cancer; 2003 Oct; 106(6):913-8. PubMed ID: 12918069
[TBL] [Abstract][Full Text] [Related]
15. TP53, p14ARF, p16INK4a and H-ras gene molecular analysis in intestinal-type adenocarcinoma of the nasal cavity and paranasal sinuses.
Perrone F; Oggionni M; Birindelli S; Suardi S; Tabano S; Romano R; Moiraghi ML; Bimbi G; Quattrone P; Cantu G; Pierotti MA; Licitra L; Pilotti S
Int J Cancer; 2003 Jun; 105(2):196-203. PubMed ID: 12673679
[TBL] [Abstract][Full Text] [Related]
16. INK4a-ARF alterations and p53 mutations in hepatocellular carcinomas.
Tannapfel A; Busse C; Weinans L; Benicke M; Katalinic A; Geissler F; Hauss J; Wittekind C
Oncogene; 2001 Oct; 20(48):7104-9. PubMed ID: 11704835
[TBL] [Abstract][Full Text] [Related]
17. Placing mitochondrial DNA mutations within the progression model of type I endometrial carcinoma.
Guerra F; Kurelac I; Cormio A; Zuntini R; Amato LB; Ceccarelli C; Santini D; Cormio G; Fracasso F; Selvaggi L; Resta L; Attimonelli M; Gadaleta MN; Gasparre G
Hum Mol Genet; 2011 Jun; 20(12):2394-405. PubMed ID: 21470976
[TBL] [Abstract][Full Text] [Related]
18. Assessment of Promoter Hypermethylation and Expression Profile of P14ARF and MDM2 Genes in Patients With Pterygium.
Arish M; Kordi-Tamandani DM; Sangterash MH; Poyandeh R
Eye Contact Lens; 2016 Jan; 42(1):e4-7. PubMed ID: 26020483
[TBL] [Abstract][Full Text] [Related]
19. Mutational analysis of selected genes in the TGFbeta, Wnt, pRb, and p53 pathways in primary uveal melanoma.
Edmunds SC; Kelsell DP; Hungerford JL; Cree IA
Invest Ophthalmol Vis Sci; 2002 Sep; 43(9):2845-51. PubMed ID: 12202501
[TBL] [Abstract][Full Text] [Related]
20. Single CpG hypermethylation, allele methylation errors, and decreased expression of multiple tumor suppressor genes in normal body cells of mutation-negative early-onset and high-risk breast cancer patients.
Böck J; Appenzeller S; Haertle L; Schneider T; Gehrig A; Schröder J; Rost S; Wolf B; Bartram CR; Sutter C; Haaf T
Int J Cancer; 2018 Sep; 143(6):1416-1425. PubMed ID: 29659014
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
